http://www.fpnotebook.com/
H2 Receptor Antagonist
Aka: H2 Receptor Antagonist, H2 Antagonist, H2 Blocker, Ranitidine, Zantac, Cimetidine, Tagamet, Nizatidine, Axid, Famotidine, Pepcid- Mechanism
- Inhibits histamine action at parietal cell H2 receptor
- Decreases basal and food stimulated acid secretion
- Inhibits 50-80% of daily gastric acid secretion
- Preparations
- Ranitidine (Zantac)
- Bolus IV Dosing: 50 mg IV q6-8h
- Continuous IV Dosing: 6.25 mg/h IV
- Oral Dosing: 150 mg PO bid
- Cimetidine (Tagamet)
- Bolus parenteral dosing: 300 mg IV or IM q6h
- Continuous IV Dosing: 37.5 mg/h IV
- Oral Dosing: 400 mg PO bid
- Famotidine (Pepcid)
- Oral dosing: 20 to 40 mg PO bid
- Nizatidine (Axid)
- Oral dosing: 150 mg PO bid
- Ranitidine (Zantac)
- Efficacy
- Disadvantages
- Even generic costs still approch Proton Pump Inhibitors
- (2003) Red Book, Medical Economics Data, Montvale, NJ
- Even generic costs still approch Proton Pump Inhibitors
- Adverse Effects
- Cimetidine has more drug interactions and side effects
| Medication Costs | ||
|---|---|---|
| RANITIDINE (on 2/10/2012 at Target.com) | ||
| RANITIDINE 150 MG Tablet | #30 for $4.00 | ($0.13/unit) |
| RANITIDINE 300 MG Tablet | #30 for $4.00 | ($0.13/unit) |
| CIMETIDINE (on 2/10/2012 at Target.com) | ||
| CIMETIDINE 800 MG* Tablet | #30 for $4.00 | ($0.13/unit) |
| FAMOTIDINE (on 2/10/2012 at Target.com) | ||
| FAMOTIDINE 20 MG Tablet | #30 for $4.00 | ($0.13/unit) |
| Ranitidine HCl (on 2/9/2012 at DrugStore.com) | ||
| Ranitidine HCl 15mg/ml Syrup | #30 for $29.99 | ($1.00/unit) |
| Ranitidine HCl 300mg Capsules | #30 for $30.99 | ($1.03/unit) |
| Ranitidine HCl 150mg Capsules | #60 for $50.99 | ($0.85/unit) |
| Ranitidine HCl 150mg Tablets | #90 for $17.99 | ($0.20/unit) |
| Ranitidine HCl 300mg Tablets | #30 for $15.99 | ($0.53/unit) |
| Ranitidine 75 (on 2/9/2012 at DrugStore.com) | ||
| Ranitidine 75 30 75mg Tablets Box | #1 for $13.99 | ($13.99/unit) |
| Zantac (on 2/9/2012 at DrugStore.com) | ||
| Zantac 150mg Tablets | #60 for $259.00 | ($4.32/unit) |
| Zantac 15mg/ml Syrup | #300 for $224.99 | ($0.75/unit) |
| Zantac 300mg Tablets | #30 for $240.99 | ($8.03/unit) |
| Zantac EFFERdose (on 2/9/2012 at DrugStore.com) | ||
| Zantac EFFERdose 25mg Effervescent Tabs | #60 for $241.00 | ($4.02/unit) |
| Cimetidine (on 2/9/2012 at DrugStore.com) | ||
| Cimetidine 300mg Tablets | #100 for $16.66 | ($0.17/unit) |
| Cimetidine 400mg Tablets | #90 for $31.99 | ($0.36/unit) |
| Cimetidine 200mg Tablets | #30 for $18.99 | ($0.63/unit) |
| Cimetidine HCl (on 2/9/2012 at DrugStore.com) | ||
| Cimetidine HCl 300mg/5ml Solution | #237 for $35.99 | ($0.15/unit) |
| Tagamet (on 2/9/2012 at DrugStore.com) | ||
| Tagamet 300mg Tablets | #60 for $81.99 | ($1.37/unit) |
| Nizatidine (on 2/9/2012 at DrugStore.com) | ||
| Nizatidine 300mg Capsules | #30 for $54.00 | ($1.80/unit) |
| Nizatidine 150mg Capsules | #60 for $51.98 | ($0.87/unit) |
| Nizatidine 15mg/ml Solution | #473 for $272.00 | ($0.58/unit) |
| Zymaxid (on 2/9/2012 at DrugStore.com) | ||
| Zymaxid 0.5% Solution 2.5ml Bottle | #1 for $96.89 | ($96.89/unit) |
| Maxidex (on 2/9/2012 at DrugStore.com) | ||
| Maxidex 0.1% Suspension 5ml Bottle | #1 for $61.36 | ($61.36/unit) |
| Axid (on 2/9/2012 at DrugStore.com) | ||
| Axid 15mg/ml Solution | #480 for $409.84 | ($0.85/unit) |
| Axid 150mg Capsules | #60 for $172.98 | ($2.88/unit) |
| Axid 300mg Capsules | #30 for $169.98 | ($5.67/unit) |
| Famotidine (on 2/9/2012 at DrugStore.com) | ||
| Famotidine 20mg Tablets | #30 for $19.99 | ($0.67/unit) |
| Famotidine 40mg Tablets | #90 for $18.98 | ($0.21/unit) |
| Famotidine 40mg/5ml Suspension 50ml Bottle | #1 for $155.98 | ($155.98/unit) |
| Pepcid (on 2/9/2012 at DrugStore.com) | ||
| Pepcid 30 20mg Tablets Bottle | #1 for $71.99 | ($71.99/unit) |
| Pepcid 30 40mg Tablets Bottle | #1 for $125.99 | ($125.99/unit) |
| Pepcid 40mg/5ml Suspension 50ml Bottle | #1 for $175.99 | ($175.99/unit) |
| FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. | ||
Tagamet (C0592157) |
|
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D002927 |
| English | tagamet, Tagamet |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Nizatidine (C0085154) |
|
|---|---|
| Definition (MSH) | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. |
| Definition (NCI) | A competitive and reversible histamine H2-receptor antagonist with antacid activity. Nizatidine inhibits the histamine H2-receptors located on the basolateral membrane of the gastric parietal cell, thereby reducing basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D016567 |
| SnomedCT | 108664005, 386887009 |
| English | Nizatidine, N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine, 1,1-Ethenediamine, N-(2-(((2-((dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-, nizatidine, nizatidine (medication), histamine-2 receptor antagonists nizatidine, NIZATIDINE, Nizatidine [Chemical/Ingredient], Nizatidine (product), Nizatidine (substance) |
| Swedish | Nizatidin |
| Czech | nizatidin |
| Finnish | Nitsatidiini |
| Russian | NIZATIDIN, НИЗАТИДИН |
| Japanese | ニザチジン |
| Polish | Nizatydyna |
| Spanish | nizatidina (producto), nizatidina (sustancia), nizatidina, Nizatidina |
| French | Nizatidine |
| German | Nizatidin |
| Italian | Nizatidina |
| Portuguese | Nizatidina |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Axid (C0678129) |
|
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D016567 |
| English | axid, Axid |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Cimetidine (C0008783) |
|
|---|---|
| Definition (CSP) | histamine congener; competitively inhibits histamine binding to H2 receptors, inhibits gastric acid secretion, pepsin, and gastrin output, and blocks the activity of cytochrome P-450. |
| Definition (NCI) | A drug usually used to treat stomach ulcers and heartburn. It is also commonly used in a regimen to prevent allergic reactions. |
| Definition (NCI) | A histamine H(2)-receptor antagonist. Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production. Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04) |
| Definition (MSH) | A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRINS output. It also blocks the activity of CYTOCHROME P-450 which might explain proposals for use in NEOADJUVANT THERAPY. |
| Definition (PDQ) | A histamine H(2)-receptor antagonist. Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production. Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39185&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39185&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C374" NCI Thesaurus) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D002927 |
| SnomedCT | 373541007, 83532008 |
| English | Cimetidine, N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine, cimetidine, Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-, N-Cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine, histamine-2 receptor antagonists cimetidine, cimetidine (medication), CIMETIDINE, Guanidine, N''-Cyano-N-Methyl-N'-(2-(((5-Methyl-1h-Imidazol-4-Yl)Methyl)Thio)Ethyl)-, Cimetidine [Chemical/Ingredient], Cimetidine (product), Cimetidine (substance) |
| Swedish | Cimetidin |
| Czech | cimetidin |
| Finnish | Simetidiini |
| Russian | TSIMETIDIN, ЦИМЕТИДИН |
| Japanese | シメチジン |
| Croatian | CIMETIDIN |
| Polish | Cymetydyna |
| Spanish | cimetidina (producto), cimetidina (sustancia), cimetidina, Cimetidina |
| French | Cimétidine |
| German | Cimetidin |
| Italian | Cimetidina |
| Portuguese | Cimetidina |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Famotidine (C0015620) |
|
|---|---|
| Definition (NCI) | A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli. |
| Definition (MSH) | A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D015738 |
| SnomedCT | 387211002, 39128000 |
| English | Famotidine, Propanimidamide, 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)-, famotidine, famotidine (medication), histamine-2 receptor antagonists famotidine, FAMOTIDINE, Famotidine [Chemical/Ingredient], Famotidine (product), Famotidine (substance) |
| Swedish | Famotidin |
| Czech | famotidin |
| Finnish | Famotidiini |
| Russian | FAMOTIDIN, ФАМОТИДИН |
| Japanese | ファモチジン |
| Croatian | FAMOTIDIN |
| Polish | Famotydyna |
| Spanish | famotidina (producto), famotidina (sustancia), famotidina, Famotidina |
| French | Famotidine |
| German | Famotidin |
| Italian | Famotidina |
| Portuguese | Famotidina |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Pepcid (C0678119) |
|
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D015738 |
| English | pepcid, Pepcid |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Zantac (C0592278) |
|
|---|---|
| Definition (CHV) | brand name of an heartburn medication |
| Definition (CHV) | brand name of an heartburn medication |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D011899 |
| English | zantac, zantac [brand name], Zantac |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Ranitidine (C0034665) |
|
|---|---|
| Definition (CHV) | a kind of antiacid drug |
| Definition (CHV) | a kind of antiacid drug |
| Definition (MSH) | A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. |
| Definition (CSP) | N-2-(5-dimethylamino)methyl-2- furanylmethyl thioethyl-N'-methyl-2-nitro-1,1 -ethenediamine; cimetidine analog; H2 histamine receptor antagonist used to treat gastric ulcers. |
| Definition (NCI) | A member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D011899 |
| SnomedCT | 372755005, 48174005 |
| English | Ranitidin, Ranitidine, N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine, ranitidine, 1,1-Ethenediamine, N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-, N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine, ranitidine (medication), histamine-2 receptor antagonists ranitidine, RANITIDINE, Ranitidine [Chemical/Ingredient], ranitidin, Ranitidine (product), Ranitidine (substance) |
| Swedish | Ranitidin |
| Czech | ranitidin |
| Finnish | Ranitidiini |
| Russian | RANITIDIN, РАНИТИДИН |
| Japanese | ラニチジン |
| Croatian | RANITIDIN |
| Polish | Ranitydyna |
| Spanish | ranitidina (producto), ranitidina (sustancia), ranitidina, Ranitidina |
| French | Ranitidine |
| German | Ranitidin |
| Italian | Ranitidina |
| Portuguese | Ranitidina |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |